I was told 3 weeks ago that there has been a problem with the Oxford jab. Apparantly there has been a cock-up in the stage 3 trials data. They were supposed to be giving 2 equal strength jabs 3 weeks apart. However, the evaluation of the strength of one of them (not sure if it was the first or second) was wrong, and the effect was that one or other of the jabs was only half strength. That's where the reports that a half jab followed by a full jab (or vive verca) increases the efficacy from 60% to 95%.
So now the UK drugs authority are having to review the data and decide if the phase 3 trials have to be repeated, this time with 2 equal doses, or whether they can go with the data as presented. Foreign drug authorities have the same data, and will have to come to their own conclusion. If the phase 3 does have to be repeated, then it delays the Oxford jab roll out for at least 3 months which is a problem for the UK because we've ordered 100M doses of Oxford, vs 7M of the Moderna and 40M of the BioNTech jab.
I've no idea whether the trial will have to be repeated, but the delay in approving the Oxford jab doesn't look good to me. It was only one week behind the BioNTech, and ahead of the Moderna in being presented to the regulator, yet both these are now in use and it's all gone quiet on the Oxford front.